Investment
Features
FeesSafety
Academy
More
Pluang+

Compare McKesson Corporation (MCK) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance

McKesson CorporationTrade
State Street SPDR S&P Biotech ETFTrade

Price performance (Past 24H)

Key statistics

McKesson Corporation vs State Street SPDR S&P Biotech ETF — how do they compare? McKesson Corporation trades at $884 (market cap $105.14B), while State Street SPDR S&P Biotech ETF trades at $159.31. The key difference: McKesson Corporation pays a 0.42% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, McKesson Corporation nearer its low. Which is the better fit depends on your goals.

MCKXBI
Market Cap
$105.14B
Sector
HealthBroad Market / Factor
52-Week High
$995.69$164.28
52-Week Low
$659.01$86.92
Enterprise Value
$111.67B
Dividend Yield
0.42%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

McKesson Corporation

McKesson (MCK) trades at $889.01, up 1.04% today, with a bullish technical outlook and strong institutional support. Recent Q1 2027 earnings beat expectations, with EPS of $9.93 versus $9.56, driven by specialty drug growth and oncology performance. Revenue reached $359.05B in 2025, with net income of $3.30B, though margins remain thin. The company raised full-year guidance, reflecting operational momentum.

The stock offers upside to the consensus price target of $990.67, supported by 80% analyst buy ratings. Key risks include reliance on pharmaceutical distribution margins, regulatory pressures, and competitive threats. Earnings consistency and cost discipline are critical for sustaining valuation multiples amid healthcare sector volatility.

State Street SPDR S&P Biotech ETF

XBI trades at $158.81, up 0.49% today, with a bullish technical signal supported by moving averages. The ETF shows strong momentum with a 17% monthly gain and 75% annual return, driven by biotech sector strength. Analyst coverage is limited to one hold rating, while recent news highlights institutional buying interest and positive sector developments including M&A activity and drug trial successes.

The outlook remains positive given biotech's breakout from multi-year bear markets, though elevated volatility and policy risks persist. Key opportunities include AI-driven drug discovery and sustained M&A momentum, while risks involve sector-specific volatility and regulatory uncertainty. The ETF's equal-weight approach provides diversified exposure to biotech innovation.

Returns comparison

Trailing returns across standard periods

About McKesson Corporation

McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.

Read more on MCK

About State Street SPDR S&P Biotech ETF

XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.

Read more on XBI